Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia.
COVID-19 vaccine
ChAdOx1-S
Oxford-AstraZeneca vaccine
SARS-CoV-2
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
28
06
2021
revised:
09
07
2021
accepted:
22
07
2021
pubmed:
29
7
2021
medline:
29
9
2021
entrez:
28
7
2021
Statut:
ppublish
Résumé
The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period.
Identifiants
pubmed: 34320413
pii: S1201-9712(21)00608-1
doi: 10.1016/j.ijid.2021.07.052
pmc: PMC8310569
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-362Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Int J Antimicrob Agents. 2020 May;55(5):105968
pubmed: 32259576
Travel Med Infect Dis. 2020 Nov - Dec;38:101901
pubmed: 33049360
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
Mol Ther. 2021 Mar 3;29(3):898-900
pubmed: 33571463
Lancet. 2021 May 29;397(10289):2043-2046
pubmed: 33991480
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Travel Med Infect Dis. 2021 Sep-Oct;43:102119
pubmed: 34133965
J Infect Dis. 2013 Aug 1;208(3):418-22
pubmed: 23633407
Vaccines (Basel). 2021 Apr 16;9(4):
pubmed: 33923530
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
N Engl J Med. 2021 Apr 22;384(16):1577
pubmed: 33596349
Annu Rev Cell Dev Biol. 2017 Oct 6;33:577-599
pubmed: 28992436
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088